Eur Rev Med Pharmacol Sci 2020; 24 (23): 11987-11987
DOI: 10.26355/eurrev_202012_23959

miR-181a down-regulates MAP2K1 to enhance adriamycin sensitivity in leukemia HL-60 cells

J.-J. Wang, J.-P. Yu

Department of Laboratory, Nuclear Industry 215 Hospital of Shaanxi Province, Xianyang, Shanxi, China.

Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, “miR-181a down-regulates MAP2K1 to enhance adriamycin sensitivity in leukemia HL-60 cells, by J.-J. Wang, J.-P. Yu, published in Eur Rev Med Pharmacol Sci 2019; 23 (6): 2497-2504–DOI: 10.26355/eurrev_201903_17397–PMID: 30964176” has been withdrawn.

The Publisher apologizes for any inconvenience this may cause.

https://www.staging.europeanreview.org/article/17397

Free PDF Download

To cite this article

J.-J. Wang, J.-P. Yu
miR-181a down-regulates MAP2K1 to enhance adriamycin sensitivity in leukemia HL-60 cells

Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 23
Pages: 11987-11987
DOI: 10.26355/eurrev_202012_23959

Keywords Related articles:

  1. miR-181a down-regulates MAP2K1 to enhance adriamycin sensitivity in leukemia HL-60 cells
  2. Increased miR-142 and decreased DJ-1 enhance the sensitivity of pancreatic cancer cell to adriamycin
  3. MicroRNA-577 promotes the sensitivity of chronic myeloid leukemia cells to imatinib by targeting NUP160
  4. Knockdown of PRAME enhances adriamycin-induced apoptosis in chronic myeloid leukemia cells
  5. TUG1 weakens the sensitivity of acute myeloid leukemia cells to cytarabine by regulating miR-655-3p/CCND1 axis